FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963586225> ?p ?o ?g. }

• W1963586225 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLBackground: CXCR2 plays an important role in inflammation, and stimulation of CXCR2-expressing endothelial cells by ELR+ CXC chemokines promotes angiogenesis. Our goal was to study the expression of CXCR2 by tumor cells and its impact on prognosis in NSCLC. Material and Methods: CXCR2 expression was determined using immunohistochemistry and a large set of tissue microarray including 458 NSCLC. The association between cytoplasmic CXCR2 (cCXCR2) expression in tumor cells and clinico-pathological factors as well as survival was analyzed. Distribution of CXCR2 and its ligands (IL8, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL7) gene expression was studied using publicly available gene expression profiles from 52 NSCLC cell lines ([GSE4824][1]) and 444 lung adenocarcinomas (adc) (NCI Director's Challenge). To summarize the effect of CXCR2/CXCR2 ligands biological axis, Principal Component Analysis (PCA) and unsupervised hierarchical clustering were performed using CXCR2 and its ligands gene expression in both cell lines and lung adc. The first Principal Component (PC1) was correlated (Pearson) with the whole genome in 52 NSCLC cell lines. All genes were ranked according to their correlation with PC1, and used for Gene Set Enrichment Analysis (GSEA) “pre-ranked” analysis. Results: Using the median of expression to dichotomize the patients in a high versus low expression group, 238 (52.1%) tumors expressed high cCXCR2. No association was observed with gender, race, smoking habits, histology, and stage. High cCXCR2 was associated with overall survival (Hazard ratio (HR) 1.5696; confidence interval (CI)=1.176-2.096, p-value=0.002) and recurrence-free survival (HR 1.321; CI=1.027-1.698, p-value=0.030) in a univariate Cox proportional hazards (CPH) model. High cCXCR2 remained significant for overall in a multicovariate CPH after adjusting for age, gender, histology, stage, neoadjuvant chemotherapy for overall survival (HR 1.465; CI=1.088-1.972, p-value=0.012) and a trend was observed for recurrence-free survival (HR 1.261; CI=0.973-1.633, p-value=0.080). Gene expression distribution of CXCR2 and its ligands were strikingly similar in cell lines and lung adc. In both cases, hierarchical clustering showed a cluster mostly driven by CXCR2, CXCL5, and CXCL7, representing 20% of the samples. PC1 accounted for 48.25 and 46.15% of the variation of the PCA in cell lines and lung adc respectively. KRAS and NFKB oncogenic pathways were the top 2 gene sets associated with PC1. Using the median as a cutoff, PC1 was associated with a worse overall survival in 444 lung adc (Log-rank P=0.006). Conclusion: cCXCR2 expression in NSCLC tumor cells is frequent and associated with an adverse outcome. CXCR2/CXCR2 ligands biological axis may be associated with an activation of KRAS and NFKB pathways, and a poor prognosis in lung adc. Funding Source: Department of Defense-VITAL.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 392. doi:10.1158/1538-7445.AM2011-392 [1]: /lookup/external-ref?link_type=NCBIGEO&access_num=GSE4824&atom=%2Fcanres%2F71%2F8_Supplement%2F392.atom" @default.
• W1963586225 created "2016-06-24" @default.
• W1963586225 creator A5009105122 @default.
• W1963586225 creator A5018202477 @default.
• W1963586225 creator A5022672424 @default.
• W1963586225 creator A5023828287 @default.
• W1963586225 creator A5026901529 @default.
• W1963586225 creator A5028085268 @default.
• W1963586225 creator A5039834119 @default.
• W1963586225 creator A5048380048 @default.
• W1963586225 creator A5065373099 @default.
• W1963586225 creator A5067386747 @default.
• W1963586225 creator A5085188591 @default.
• W1963586225 date "2011-04-15" @default.
• W1963586225 modified "2023-09-25" @default.
• W1963586225 title "Abstract 392: CXCR2 expression in tumor cells is associated with an adverse outcome in a large set of non-small-cell lung cancer (NSCLC)" @default.
• W1963586225 doi "https://doi.org/10.1158/1538-7445.am2011-392" @default.
• W1963586225 hasPublicationYear "2011" @default.
• W1963586225 type Work @default.
• W1963586225 sameAs 1963586225 @default.
• W1963586225 citedByCount "0" @default.
• W1963586225 crossrefType "proceedings-article" @default.
• W1963586225 hasAuthorship W1963586225A5009105122 @default.
• W1963586225 hasAuthorship W1963586225A5018202477 @default.
• W1963586225 hasAuthorship W1963586225A5022672424 @default.
• W1963586225 hasAuthorship W1963586225A5023828287 @default.
• W1963586225 hasAuthorship W1963586225A5026901529 @default.
• W1963586225 hasAuthorship W1963586225A5028085268 @default.
• W1963586225 hasAuthorship W1963586225A5039834119 @default.
• W1963586225 hasAuthorship W1963586225A5048380048 @default.
• W1963586225 hasAuthorship W1963586225A5065373099 @default.
• W1963586225 hasAuthorship W1963586225A5067386747 @default.
• W1963586225 hasAuthorship W1963586225A5085188591 @default.
• W1963586225 hasConcept C121608353 @default.
• W1963586225 hasConcept C126322002 @default.
• W1963586225 hasConcept C12823836 @default.
• W1963586225 hasConcept C13373296 @default.
• W1963586225 hasConcept C142724271 @default.
• W1963586225 hasConcept C143998085 @default.
• W1963586225 hasConcept C193270364 @default.
• W1963586225 hasConcept C2776256026 @default.
• W1963586225 hasConcept C2776914184 @default.
• W1963586225 hasConcept C2780394083 @default.
• W1963586225 hasConcept C502942594 @default.
• W1963586225 hasConcept C71924100 @default.
• W1963586225 hasConcept C84913492 @default.
• W1963586225 hasConcept C86803240 @default.
• W1963586225 hasConcept C96525457 @default.
• W1963586225 hasConceptScore W1963586225C121608353 @default.
• W1963586225 hasConceptScore W1963586225C126322002 @default.
• W1963586225 hasConceptScore W1963586225C12823836 @default.
• W1963586225 hasConceptScore W1963586225C13373296 @default.
• W1963586225 hasConceptScore W1963586225C142724271 @default.
• W1963586225 hasConceptScore W1963586225C143998085 @default.
• W1963586225 hasConceptScore W1963586225C193270364 @default.
• W1963586225 hasConceptScore W1963586225C2776256026 @default.
• W1963586225 hasConceptScore W1963586225C2776914184 @default.
• W1963586225 hasConceptScore W1963586225C2780394083 @default.
• W1963586225 hasConceptScore W1963586225C502942594 @default.
• W1963586225 hasConceptScore W1963586225C71924100 @default.
• W1963586225 hasConceptScore W1963586225C84913492 @default.
• W1963586225 hasConceptScore W1963586225C86803240 @default.
• W1963586225 hasConceptScore W1963586225C96525457 @default.
• W1963586225 hasLocation W19635862251 @default.
• W1963586225 hasOpenAccess W1963586225 @default.
• W1963586225 hasPrimaryLocation W19635862251 @default.
• W1963586225 hasRelatedWork W10340544 @default.
• W1963586225 hasRelatedWork W11468223 @default.
• W1963586225 hasRelatedWork W11779430 @default.
• W1963586225 hasRelatedWork W12228877 @default.
• W1963586225 hasRelatedWork W13038688 @default.
• W1963586225 hasRelatedWork W32782 @default.
• W1963586225 hasRelatedWork W6056146 @default.
• W1963586225 hasRelatedWork W6095507 @default.
• W1963586225 hasRelatedWork W6834028 @default.
• W1963586225 hasRelatedWork W7869943 @default.
• W1963586225 isParatext "false" @default.
• W1963586225 isRetracted "false" @default.
• W1963586225 magId "1963586225" @default.
• W1963586225 workType "article" @default.